semaglutide 5/0.5 mg/ml / Cyanocobalamin Injection Wegovy 0.5 mg/0.5 mL pre-filled

Clinical studies have demonstrated that tirzepatide can lead to significant improvements in blood sugar control by increasing insulin secretion in response to food and reducing glucose release from the liver

To meet surging demand, many companies rely on compounded semaglutide - unapproved versions of the active ingredient in Ozempic and Wegovy - produced by third-party pharmacies

Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P

Clinical trials, including the STEP 1 trial, showed that participants using Wegovy combined with diet and lifestyle changes achieved an average of 14.9 percent body weight reduction over 68 weeks